|
Business opportunities will rely on the Company executing its polymerization, pyrolization and assembly outsourcing plans. The Company's plans to produce over 1,000 Aqua Cells in the next twelve months are dependent on financing and expanding outsourcing capacities. |
|
To meet the 2005 and 2006 requirements, the Company must obtain the working capital necessary for its planned Texas manufacturing facility, capital equipment and required personnel. To meet these needs, capital must be received or committed by September 30, 2005. |
|
The Company has expanded its commitment to developing a team of strategic partners by providing demonstration AquaCells for technology and application testing. To date, demonstration AquaCells are implemented in Japan, Australia, Holland and Canada, as well as the U.S. Ongoing CDT application development is active at Texas A&M University, Texas Water Development Board, Colorado School of Mines, U.S. Bureau of Reclamation, as well as several multi-national corporate strategic partners' identified applications. |
|
There can be no assurances given that the Company will be successful in generating sufficient revenues from its planned activities or in raising sufficient capital to allow it to continue as a going concern which contemplates increased operating expenses, acquisition of assets and the disposition of liabilities in the normal course of business. These factors can affect the ability of the Company to implement its general business plan including the completion of the required manufacturing facilities and continued proprietary CDT product improvements. |
|
Note 2 Summary of Significant Accounting Policies and Practices |
|
(a) Description of Business |
|
Capacitive Deionization Technology Systems, Inc. (Formerly FarWest Group, Inc.) (the "Company" or "CDT Systems, Inc.") was organized under the laws of the state of Nevada in July 1996 to serve as a water technology company. |
|
In January 1997, the Company entered into a manufacturing and marketing license agreement with Lawrence Livermore National Laboratories ("Lawrence Livermore") whereby the Company obtained the rights to Lawrence Livermore's patented Capacitive Deionization Technology ("CDT"). The Company has the rights to develop and manufacture a carbon aerogel CDT product for commercial use in the desalination, filtration and purification of water. The manufacturing and marketing license is effective for the life of the patents (up to 17 years). To maintain the license the Company must make contracted annual royalty payments to Lawrence Livermore beginning at $25,000 per year, then becoming a percentage of revenue. |
|
(b) Net Loss per Weighted Average Share |
|
Net loss per weighted average share is calculated using the weighted average number of shares of common stock outstanding. |
|
(c) Basis of Presentation |
|
The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB of Regulations S-B. They do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements for the year ended December 31, 2004 which has been included in the Company's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission. The interim unaudited financial statements should be read in conjunction with those financial statements to be included in the Form 10-KSB. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2005 are not indicative of the results that may be expected for the year ending December 31, 2005. |
|
(d) Stock-Based Compensation |
The Company applies the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations, in accounting for its stock-based compensation plans. Under Opinion 25, compensation cost is measured as the excess, if any, of the market price of the Company's stock at the date of the grant above the amount an employee must pay to acquire the stock. No compensation expense is recognized when the exercise price is equal to the market value of the stock on the day of the grant. The Financial Standards Board ("FASB") published SFAS No. 123, "Accounting for Stock-Based Compensation" (SFAS No. 123) on January 1, 1996 which encourages, but does not require, companies to recognize compensation expense for grants of stock, stock options and other equity instruments to employees based on new fair value accounting rules. Companies that choose not to adopt the new rules will continue to apply the existing rules, but will be required to disclose pro forma net income under the new method. |
|
The Company issued no options or warrants to employees during the quarter ended June 30, 2005. During the quarter ended March 31, 2005, the Company issued 150,000 options to an employee, exercisable over five years at $.22 per share. The effect on pro forma net loss and net loss per share was nominal. |
|
Item 2 Management's discussion and analysis of financial condition and results of operations. |
|
Information regarding and factors affecting forward-looking statements. Forward-looking statements include statements concerning plans, goals, strategies, future events or performances and underlying assumptions and other statements, which are other than statements of historical fact. Certain statements contained herein are forward-looking statements and, accordingly, involve risk and uncertainties, which could cause the actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company's expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, management's examination of historical trends, data contained in the Company's records and other data available from third parties, but there can be no assurance that management's expectations, beliefs or projections will result, or be achieved, or accomplished. |
|
Results of operations |
|
To date the Company has recognized nominal revenue. General and administrative expenses were increased to $102,346 in the second quarter of 2005 compared to $89,686 in the second quarter of 2004, principally due to legal and consulting fees relating to the Company's current financing efforts. Research and development expenditures for the second quarter of 2005 increased to $338,920 compared to $75,195 in the second quarter of 2004. R & D expenses totaled 70% of operating expenses in the second quarter of 2005 compared to 41% in 2004. |
|
Liquidity and capital resources. |
|
Management recognizes the requirement for additional investment to execute the Company's business plan and complete the necessary manufacturing and research facilities. Financing transactions are currently being negotiated. These include an investment bank providing PIPE (Private Investment in a Public Entity) funding necessary to finance the manufacturing facility, an equity participation international manufacturing joint venture, and long-term asset financing. There is no certainty that this funding will be completed. |
|
|
|
Item 3. Controls and Procedures |
|
(a) Evaluation of disclosure controls and procedures. |
|
The Company's principal executive and financial officers have conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 as of a date (the "Evaluation Date") the end of the period. Based upon that evaluation, the Company's principal executive and financial officers have concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective in ensuring that all material information relating to the Company required to be filed in this quarterly report has been made known to them in a timely manner. |
|
(b) Changes in internal controls. |
|
There have been no significant changes made in the Company's internal controls or in other factors that has or will likely materially affect internal controls over financial reporting. |
|
Part II |
|
Item 1 Legal Proceedings |
|
None. |
|
Item 2 Unregistered Sales of Equity Securities |
|
During the first quarter 2005, three-year convertible debentures, convertible at $.50 per share, provided $31,500 to the Company. In addition, a private placement to individual accredited investors of 1,178,300 shares of the Company's rule 144 common stock was completed. The private placement provided the Company $230,000 in cash through the issuance of 864,834 shares; 69,800 shares were issued for $17,450 of engineering services, 197,666 shares were issued for $49,417 of professional services; and 46,000 shares were issued to settle $10,000 of notes payable. |
|
During the second quarter 2005, three-year convertible debentures, convertible at $.50 per share, provided $20,745 to the Company. In addition, a private placement to individual accredited investors of 1,639,647 shares of the Company's rule 144 common stock was completed. The private placement provided the Company $67,100 in cash through the issuance of 209,397 shares; 27,175 shares were issued for $7,816 of engineering services, 109,375 shares were issued for $34,054 of professional services, 800,000 shares were issued to settle $200,000 of notes payable and 493,700 shares were issued to settle $123,425 in accrued interest. |
|
During the first quarter 2004, three-year convertible debentures, convertible at $.50 per share, provided $132,425 to the Company. In addition, a private placement of 1,093,700 shares of the Company's rule 144 common stock was completed. The private placement provided the Company $113,300 in cash through the issuance of 461,200 shares; 140,000 shares were issued for $35,000 of engineering services, 276,500 shares were issued for $69,125 of professional services; and 216,000 shares were issued to settle $50,000 of accounts payable and $4,000 of wages payable. |
|
During the second quarter 2004, three-year convertible debentures, convertible at $.20 per share, provided $5,000 to the Company. In addition, a private placement of 337,400 shares of the Company's rule 144 common stock was completed. The private placement provided the Company $35,000 in cash through the issuance of 160,000 shares; 108,400 shares were issued for $27,100 of professional services and 69,000 shares were issued for $17,250 of engineering services. |
|
Item 3. Defaults Upon Senior Securities |
|
As of June 30, 2005, the Company is in repayment default on the principal and interest on certain of its notes payable in the following amounts: Principal -- $417,816; Interest -- $70,840. |
|
Item 4. Submission of Matters to a Vote of Security Holders |
|
The Company's Annual Meeting of Stockholders was held on July 14, 2005. At the meeting: |
|
(i) The following persons were elected as directors of the Company, to serve until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified, each receiving the number of votes set forth opposite their names: |
|